WELCOME
ShapingShaping
thethe
FutureFuture
ofof
MentalMental
Health.Health.
Palo Santo invests in next-generation neuroscience companies developing breakthrough therapeutics and technologies for mental health.
THE TIME IS NOW
Transforming Mental Health
Through Next-Generation
Neuroscience Targets and
Psychedelic Therapeutics
LEARN WHYThrough Next-Generation
Neuroscience Targets and
Psychedelic Therapeutics
23
Core investments
23 core investments across neuroscience therapeutics and technologies
$2.4B
Acquisition Dollars
Total value of pharma acquisitions across the portfolio (AbbVie's $1.2B acquisition of Gilgamesh's lead program, and Otsuka's $1.2B acquisition of Transcend)
08
FDA Breakthrough Therapy Designations
Eight FDA Breakthrough Therapy Designations in psychedelic medicine
350+
Clinical Trials
Over 350 FDA clinical trials involving psychedelics in progress worldwide
23
Core investments
23 core investments across neuroscience therapeutics and technologies
$2.4B
Acquisition Dollars
Total value of pharma acquisitions across the portfolio (AbbVie's $1.2B acquisition of Gilgamesh's lead program, and Otsuka's $1.2B acquisition of Transcend)
08
Breakthrough Therapy Designations
Eight FDA Breakthrough Therapy Designations in psychedelic medicine
350+
Clinical Trials
Over 350 FDA clinical trials involving psychedelics in progress worldwide
Portfolio.
From next-generation psychedelics to novel CNS targets and enabling technologies, our portfolio spans the forefront of neuroscience innovation driving new treatments for mental health
Building the Future Of Brain Health with AI-Driven Neurotechnology
Learn More
Helping Patients with Neurological & Psychiatric Disorders through Innovative Psychedelic Pharmaceuticals.
Learn More
Novel Psychedelic Analogues For the Treatment of Neuropsychiatric Conditions
Learn More
Revolutionizing short-duration psychedelic therapies for underserved medical conditions
Learn More
Reimagining brain health through new insights into synaptic biology
Learn More
Full Portfolio
Full Portfolio